Checkpoint Therapeutics (NASDAQ:CKPT) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research report report published on Thursday,Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock.

Checkpoint Therapeutics Price Performance

NASDAQ:CKPT opened at $3.43 on Thursday. The firm has a market capitalization of $154.42 million, a price-to-earnings ratio of -1.86 and a beta of 1.23. The business has a 50 day simple moving average of $2.82 and a 200-day simple moving average of $2.35. Checkpoint Therapeutics has a 1 year low of $1.36 and a 1 year high of $3.97.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). As a group, analysts expect that Checkpoint Therapeutics will post -0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Checkpoint Therapeutics

A number of institutional investors have recently modified their holdings of CKPT. Vanguard Group Inc. increased its position in Checkpoint Therapeutics by 67.4% during the 1st quarter. Vanguard Group Inc. now owns 917,894 shares of the company’s stock valued at $1,882,000 after purchasing an additional 369,586 shares during the period. 180 Wealth Advisors LLC acquired a new stake in shares of Checkpoint Therapeutics during the second quarter worth $96,000. Choreo LLC grew its stake in Checkpoint Therapeutics by 12.2% during the 2nd quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after purchasing an additional 7,080 shares during the last quarter. XTX Topco Ltd acquired a new position in Checkpoint Therapeutics in the 2nd quarter worth approximately $34,000. Finally, B. Riley Wealth Advisors Inc. raised its position in Checkpoint Therapeutics by 366.3% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock worth $493,000 after buying an additional 180,050 shares during the last quarter. 22.00% of the stock is owned by hedge funds and other institutional investors.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.